Cargando…

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

BACKGROUND: Survival-based surrogate endpoints such as progression-free survival (PFS) are commonly used in oncology clinical trials. The evaluation-time bias in the assessment of median disease progression in randomized trials has been suggested by several simulation studies, but never demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samaille, T., Moreau Bachelard, C., Coquan, E., du Rusquec, P., Paoletti, X., Le Tourneau, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733185/ https://www.ncbi.nlm.nih.gov/pubmed/34979424 http://dx.doi.org/10.1016/j.esmoop.2021.100366

Ejemplares similares

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis
por: Moreau Bachelard, Camille, et al.
Publicado: (2021)

Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021)

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
por: du Rusquec, P., et al.
Publicado: (2023)

Using median survival in meta-analysis of experimental time-to-event data
por: Hirst, Theodore C., et al.
Publicado: (2021)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

Assessment of Median and Mean Survival Time in Cancer Clinical Trials
por: Das, Ananya, et al.
Publicado: (2023)

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Gougis, Paul, et al.
Publicado: (2019)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
por: du Rusquec, Pauline, et al.
Publicado: (2019)

The gene family-free median of three
por: Doerr, Daniel, et al.
Publicado: (2017)

Nonparametric estimation of median survival times with applications to multi-site or multi-center studies
por: Rahbar, Mohammad H., et al.
Publicado: (2018)

Comparing survival curves based on medians
por: Chen, Zhongxue, et al.
Publicado: (2016)

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020)

Diarrhée aiguë
por: Samaille, C., et al.
Publicado: (2018)

Prediction of median survival time in sepsis patients by the SOFA score combined with different predictors
por: Li, Wen, et al.
Publicado: (2020)

Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times
por: Bruckner, Howard W., et al.
Publicado: (2022)

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
por: Le Tourneau, C, et al.
Publicado: (2012)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Median Neurectomy
por: Clayton, C. E.
Publicado: (1899)

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
por: Marczynski, Gabriella Taques, et al.
Publicado: (2020)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

Crucifixion and median neuropathy
por: Regan, Jacqueline M, et al.
Publicado: (2013)

Animal transport as regulated in Europe: a work in progress as viewed by an NGO
por: Bachelard, Nikita
Publicado: (2022)

Case report: Giant atypical granular cell tumor of the median nerve
por: Liu, Jun-Peng, et al.
Publicado: (2023)

Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
por: Hinchcliffe, Michael, et al.
Publicado: (2017)

Distal pancreatectomy with en bloc celiac axis resection does not improve the R0 rate or median survival time of patients with locally advanced pancreatic cancer: a systematic review and meta-analysis
por: Feng, Qingbo, et al.
Publicado: (2020)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Median Lithotomy
Publicado: (1873)

Median Lithotomy
por: Wall, Charles A.
Publicado: (1878)

Median Lithotomy
Publicado: (1884)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
por: Tizianel, Irene, et al.
Publicado: (2022)

Median Nerve Neuropathy Caused by Persistent Median Artery Thrombosis
por: Miyashima, Yusuke, et al.
Publicado: (2023)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Median artery persistence in coexistence with a bifid median nerve and interconnections of the median with the ulnar nerve and vice versa
por: Piagkou, Maria, et al.
Publicado: (2023)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study
por: Ahmadi, Ali, et al.
Publicado: (2014)

Phase change for the accuracy of the median value in estimating divergence time
por: Jamshidpey, Arash, et al.
Publicado: (2013)

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
por: Baldini, C., et al.
Publicado: (2022)

Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016
por: Knisely, Anne T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vgum6s9spqj3ctpgq958qeej32